Clinica Baviera (CBAV) Q4 2025 earnings summary

Executive summary

• Revenue increased by 12% year-over-year to €301.8 million, with net profit up 15% to €42.9 million and growth in all operating countries.

• EBITDA grew 12% to €84.5 million, and net financial position rose 39% to €42.4 million, despite significant investments and a €25 million dividend payout.

• Eleven new clinics opened across Spain, Italy, Germany, and the UK, strengthening market position and expanding the patient base.

• Share price appreciated by 59% during the year, and dividend per share remained stable at €1.57.

• Operational improvements and digital tools enhanced quality and efficiency metrics.

Financial highlights

• Consolidated revenue reached €301.8 million (+12%), with net profit at €42.9 million (+15%) and EBITDA at €84.5 million (+12%).

• Earnings per share increased to €2.58 (+12%).

• Operating expenses increased 17% to €217.2 million.

• Net financial position improved to €42.4 million (+39%).

• Dividend per share stable at €1.57.

Outlook and guidance

• Optimism for 2026, the 35th anniversary, driven by operational improvements, AI adoption, and continued digital transformation.

• Focus on expanding clinical network and maintaining leadership in ophthalmology.